Ledyard National Bank Has $10.72 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Ledyard National Bank raised its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,683 shares of the company’s stock after buying an additional 708 shares during the period. Johnson & Johnson accounts for about 1.3% of Ledyard National Bank’s investment portfolio, making the stock its 25th biggest position. Ledyard National Bank’s holdings in Johnson & Johnson were worth $10,720,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of JNJ. Lincoln Capital Corp lifted its position in Johnson & Johnson by 15.9% during the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock worth $218,000 after buying an additional 183 shares in the last quarter. Ieq Capital LLC lifted its position in Johnson & Johnson by 5.1% during the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after buying an additional 6,154 shares in the last quarter. RFG Advisory LLC lifted its position in Johnson & Johnson by 2.7% during the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after buying an additional 594 shares in the last quarter. Willis Investment Counsel lifted its position in Johnson & Johnson by 0.4% during the 4th quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock worth $58,097,000 after buying an additional 1,358 shares in the last quarter. Finally, Wambolt & Associates LLC lifted its position in Johnson & Johnson by 2.5% during the 4th quarter. Wambolt & Associates LLC now owns 14,528 shares of the company’s stock worth $2,566,000 after buying an additional 355 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Want More Great Investing Ideas?

Several research analysts recently issued reports on the stock. SVB Leerink reduced their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Credit Suisse Group upped their target price on shares of Johnson & Johnson from $168.00 to $170.00 in a research report on Friday. Atlantic Securities cut their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 19th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating on the stock. Finally, UBS Group initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price on the stock. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $173.00.

Johnson & Johnson Stock Up 0.3 %

NYSE:JNJ opened at $162.68 on Friday. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $183.35. The stock has a 50-day moving average price of $158.33 and a two-hundred day moving average price of $166.96. The stock has a market cap of $422.76 billion, a price-to-earnings ratio of 34.03, a PEG ratio of 2.78 and a beta of 0.53. The company has a current ratio of 1.07, a quick ratio of 0.77 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.51 by $0.17. The business had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. Johnson & Johnson’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.67 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.93%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 94.56%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.